Theres nothing better as an investor than owning shares of companies that improve our lives. At the top of that list is companies that help us live healthier, longer lives.
Source: Shutterstock
Back in November which seems like an eternity ago I wrote that 2020 would be the Year of Biotech. Neither I nor anyone else knew how critical medical sciences and healthcare would become just a few months later amid a worldwide pandemic.
I still see 2020 as the Year of Biotech.
These stocks have shown relative strength in the bear market, and the current crisis gives us a glimpse of the innovative breakthroughs coming our way including efforts to fight the coronavirus.
In a volatile stock market like this, you can buy most stocks at a massive discount. Big names are down 20% 30% even 50%. Some small-cap stocks have slid even more.
This rare situation has opened up an unusual buying opportunity that we havent seen for at least the past decade or longer.
Fundamentally, the investment mega-trends Im following including in my new Crisis and Opportunity Portfolio are still on track. The coronavirus has scrambled everyones plans for the moment, but it wont last. The market has recovered from every past bear market, and were seeing glimmers of hope in the number of new cases around the world.
Ive been saying for more than week now that its time to start investing in stocks again. Believe me, trying to pick an exact bottom isnt worth the risk. Instead, you have to focus on the trends that will spawn the markets next big winners.
Biotechnology is one of these unstoppable mega-trends.
In 2019, before the coronavirus was on anyones mind, investors poured $13.9 billion into biotech startups. That was $4 billion less than 2018s record-breaking number but still higher than any other year on record.
The industry was climbing to new heights as companies began using next-generation technologies like artificial intelligence (AI) to find new drugs for diseases like cancer quicker and cheaper than ever before.
Another cutting-edge technology thats been on the rise is genomics, which will usher in a new era of personalized medicine for each patient as well as speed up the creation of new drugs.
And at this particular moment, it makes sense that investors would take notice as biotechs around the world are on high alert to find better drugs and/or a vaccine to tame the coronavirus.
Indeed, the sector has held steady through the recent volatility. Its one of the broader markets top performers.
So far this year, the S&P 500 is down more than 17% while theVanEck Vectors Biotech ETF (NASDAQ:BBH) is down closer to 5.6%. Thats far better than some of the other sectors that you might think would be strong right now like household products and food and staples retailing, which are both down 15%, according to Fidelity.
Yes, many biotech stocks are down at the moment. But that sets up an incredible chance to get some of the best at a discount.
Right now, more than 140 experimental coronavirus treatments and vaccines are in the works worldwide, according to theWall Street Journal. Researchers are moving at record pace, setting up 254 clinical trials to test drugs and/or vaccines in a matter of weeks or days.
Whether a given company is a part of this effort or not, nearly every biotech has been impacted by the pandemic. For instance, clinical trials are getting pushed back while healthcare facilities around the globe have shut down for fear of spreading the virus.
But the delay is short term. And longtimeMoneyWirereaders know that we focus on the long-term big picture.
Artificial intelligence and genomics already play a key role in the biotech industry as companies try to find a workable solution for whats ailing all of us.
And unlike the recent focus on producing protective equipment and coronavirus tests that will likely fizzle after the worst has passed,the use of these technologies will only continue to grow.
My #1 stock in theCrisis and Opportunity Portfoliothat I just released last week is a great example. The company uses AI in its predictive analytics to improve patient care and lower costs for insurance companies. Part of that involves the exploding trend of telehealth.
Telehealth includes the virtual doctors visits that are keeping us all out of waiting rooms during the pandemic. But I suspect doctors and patients alike will stick with the convenience and efficiency of the service long after the current crisis passes.
This stock lost a lot of ground in the sell-off, but it is already up 33% since I recommended it last Wednesday. The company is forecast to deliver 61% annual revenue growth and has a clear path to profitability, which is important when investing in smaller companies. I see a lot more upside to come.
Finding the best small companies in the best industries like biotech that will see the biggest gains as we recover is what my newCrisis and Opportunity Portfoliois all about.
Ive handpicked the companies best positioned to soar, and were adding them strategically one by one. Thats the smartest way to buy in this still-volatile market.
The current selling is setting up amazing buying opportunities in investment trends that wont slow due to the pandemic. The key is knowingwhich ones represent the best potential over the long term.
Matthew McCall left Wall Street to actually help investors by getting them into the worlds biggest, most revolutionary trends BEFORE anyone else. The power of being first gave Matts readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA) and +1,044% in Tesla (TSLA), just to name a few. Click here to see what Matt has up his sleeve now.Matt does not directly own the aforementioned securities.
Original post:
Biotech Stocks: Big Buying Opportunities in 2020s Sector of the Year - Investorplace.com
- More Precise Classifications of NonClear Cell RCC Are Required to Improve Personalized Treatment - OncLive - September 13th, 2024
- Bahrain aims to provide residents with personalized healthcare - Healthcare IT News - September 13th, 2024
- Precision Medicine Market Is Expected To Reach Revenue Of - GlobeNewswire - September 13th, 2024
- New Graduates Leverage Genomics Education in Clinical and Research Settings - University of Colorado Anschutz Medical Campus - June 20th, 2024
- Personalized medicine is coming, but who will have access to it? - March 10th, 2024
- Personalized medicine | Definition, Origins, Examples, & Ethical ... - March 10th, 2024
- Innovating for Individual Care: The Impact of USP on Personalized Medicine - March 10th, 2024
- Live Cell Encapsulation Market To Reach USD 313.3 Million at a CAGR of 4% in 2032 - EIN News - April 23rd, 2023
- Cancer Therapeutics and Biotherapeutics Market is estimated to be US$ 506.8 billion by 2032 with a CAGR of - EIN News - April 7th, 2023
- Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News - March 13th, 2023
- Gene Therapy Market Size (USD 46.5 Bn by 2030): A Growing Industry and Its Impact on Healthcare Systems - EIN News - March 13th, 2023
- Translating the Microbiome - Inside Precision Medicine - October 15th, 2022
- Enhancing Enrollment in Biomarker-Driven Oncology and Rare Disease Trials - Applied Clinical Trials Online - October 15th, 2022
- Global Cancer/Tumor Profiling Market Research Report to 2027 - Increasing Demand for Personalized Medicine Presents Opportunities -... - October 15th, 2022
- Cambridge biotech raises $168 million to fight cancer and other diseases - The Boston Globe - October 15th, 2022
- Perlmutter Cancer Center Medical Oncologist Provides Personalized Care to People with Breast Cancer - NYU Langone Health - October 15th, 2022
- Concierge Medicine's Continued Rise Illuminated by Specialdocs Consultants at the Industry's Leading Event - PR Newswire - October 15th, 2022
- Hormone Changes: The Star of Every Stage in Women's Sleep - Medscape - October 15th, 2022
- Could Xolair Be the First Biologic Treatment for Food Allergies? - Allergic Living - October 15th, 2022
- Matching Treatments to Your Genes - The Epoch Times - October 15th, 2022
- Global Monoclonal Antibodies (mAbs) Markets, 2018-2021 & 2022-2030 - Increasing R&D Activities Aimed at the Development of Novel Therapeutic mAbs -... - October 15th, 2022
- Xcell Biosciences and aCGT Vector Collaborate to Accelerate Development of Cell and Gene Therapies - Business Wire - October 15th, 2022
- Learn Look Locate Partners with Genetic Testing Leader, Myriad Genetics, in Educational Campaign - PR Newswire - October 15th, 2022
- Important Mission By LG To Reinvent Society With Future Growth - Forbes - October 15th, 2022
- Scientists identify more than 12,000 spots in the human genome associated with height - Inverse - October 15th, 2022
- The future of cancer research | News - ND Newswire - October 15th, 2022
- Kyverna Therapeutics Names Peter Maag, Ph.D., as Chief Executive Officer - PR Newswire - October 15th, 2022
- Call for Accurate Automation in Healthcare Practices to drive the Laboratory Information Systems (LIS) Market | Future Market Insights, Inc. - Yahoo... - October 15th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Ma - Benzinga - October 15th, 2022
- Global Precision Medicine Software Market is projected to witness a healthy growth rate of 10% in the upcoming years - Bio-IT World - July 17th, 2022
- The Single-Cell Analysis Market Size To Almost Double By 2026 Due To A Rising Focus On Personalized Medicine As Per The Business Research Company's... - July 17th, 2022
- Northwell Health Partners with Google Cloud to Provide Proactive, Personalized Healthcare - PR Newswire - July 17th, 2022
- Leveraging whole blood based functional flow cytometry assays to open new perspectives for rheumatoid arthritis translational research | Scientific... - July 17th, 2022
- New Approaches Needed To Support Digitization Of Healthcare - Forbes - July 17th, 2022
- Outlook on the Microtome Global Market to 2027 - Increasing Demand for Personalized Medicine Presents Opp - Benzinga - July 17th, 2022
- Precision health perspectives - UCI News - July 17th, 2022
- The Worldwide Compound Management Industry is Expected to Reach $1.4 Billion by 2030 - ResearchAndMarkets.com - Business Wire - July 17th, 2022
- Thrive Pet Healthcare and FidoCure Announce An Expansive Pet Precision Health Partnership - Benzinga - Benzinga - July 17th, 2022
- Access to Myriad Genetics GeneSight Test Improves Depression Remission Rates In Largest Ever Mental Health PGx Randomized Controlled Trial - Yahoo... - July 17th, 2022
- Global Induced Pluripotent Stem Cell (iPSC) Market Report 2022: Rising Applications of iPSCs Fueling Industry Growth - ResearchAndMarkets.com -... - July 17th, 2022
- Research Antibodies and Reagents Market worth $16.1 Billion by 2027 Exclusive Report by MarketsandMarkets - Yahoo Finance - July 17th, 2022
- Global Custom Antibody Market Is Expected To Reach USD 742.27 Million At A CAGR Of 10.3% And Forecast To 2029 - Digital Journal - July 17th, 2022
- Personalized Medicine Coalition - Precision Medicine Advocacy and ... - June 8th, 2022
- Precision Medicine | FDA - June 8th, 2022
- Global Precision Medicine Software Market is anticipated to witness a lucrative CAGR of 10% - GlobeNewswire - June 8th, 2022
- Global Biomarkers Markets Research 2022-2027: Increased Adoption of Biomarkers in Personalized Medicine / Focus on Digital Biomarkers / Increased... - June 8th, 2022
- Every patient in this experimental drug trial saw their cancer disappear, researchers say - CBS News - June 8th, 2022
- The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the... - June 8th, 2022
- It's time to move past Aduhelm and focus on a broader Alzheimer's drug pipeline - STAT - June 8th, 2022
- Can the industry elevate the success rate of cancer trials? - OutSourcing-Pharma.com - June 8th, 2022
- Purdue Polytechnic Institute and Purdue University Global collaborating on partnership with the University of Puerto Rico - Purdue University - June 8th, 2022
- Illumina Announces Next Generation Products and Data at AGBT General Meeting to Advance Innovative Customer Solutions - PR Newswire - June 8th, 2022
- AdhereTech and Massive Bio, Two of NYC Digital Health 100 most Promising Start-Ups, Announce AI-Enabled, Patient-Centric Oncology Solutions... - June 8th, 2022
- Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022 - Endocrinology Network - June 8th, 2022
- PreludeDx Presents New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting - 69News WFMZ-TV - June 8th, 2022
- BITS Pilani Hyderabad to conduct 'Precision Medicine 2022' event tomorrow - United News of India - June 8th, 2022
- Global Laboratory Information Systems (LIS) Market to Reach US$2.4 Billion by the Year 2026 - Yahoo Finance - June 8th, 2022
- Medical Nutrition Market Promising Growth Opportunities and Forecast 2027 - Digital Journal - June 8th, 2022
- 57% of Organizations in India are at the Startup Stage of Genomics High-Performance Computing Infrastructure - APN News - June 8th, 2022
- Cellworks Singula TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies - StreetInsider.com - June 8th, 2022
- Inspiration for the laboratory of tomorrow - Chemie.de - June 8th, 2022
- Global Nanomaterials in Personalized Medicine Market (Impact Of COVID-19) Growth, Overview With Detailed Analysis 2022-2028 Queen Anne and Mangolia... - May 8th, 2022
- The global biomarkers market is expected to grow at a CAGR of 11.44%. - Yahoo Finance - May 8th, 2022
- Bioinformatics Market Size, Share, And Trends Analysis Report, By Application (Drug Development, Protein Function Analysis, Gene Therapy, Molecular... - May 8th, 2022
- Link between EBV and MS may give clues to the cause of long COVID - The Arizona Republic - May 8th, 2022
- Improving Cell Cultures with Thermoresponsive Coatings - Genetic Engineering & Biotechnology News - May 8th, 2022
- Reevaluating, Reimagining, And Reinventing Healthcare: Innovation In A Post-Pandemic World - Forbes - May 8th, 2022
- Study of Cancer Genetics to Help with Targeted Treatment - VOA Learning English - May 8th, 2022
- Increased demand for Molecular diagnostics after the COVID-19 outbreak - The Financial Express - May 8th, 2022
- CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News - January 30th, 2022
- SeqOne Genomics Closes 20M Series a to Accelerate the Deployment of Its Genomic Medicine Platform - Business Wire - January 30th, 2022
- Study: In IBS patients, cognitive behavioral therapy modulates the brain-gut microbiome and helps relieve symptoms - UB News Center - January 30th, 2022
- (New Report) Digital Genome Market In 2022 : The Increasing use in Diagnostics, Agriculture & Animal Research, Personalized Medicine, Drug... - January 30th, 2022
- Silencing a faulty gene may uncover clues to rare forms of ALS - National Institutes of Health - January 30th, 2022
- Plants, Bioprinting and Orbital Plumbing Fill Crew's Thursday Schedule - NASA - January 30th, 2022
- ClarityX DNA: The Key to Tackling Seasonal Affective Disorder - PR Web - January 30th, 2022
- Global High Performance Computing Market 2022-2027: AI, IoT, and 5G will be Major Drivers for HPC Growth as they Facilitate the Need to Process Vast... - January 30th, 2022
- A different kind of consult: pro-bono community health consulting by med students - Modern Healthcare - January 30th, 2022
- Personalized Medicine - Genome.gov - October 26th, 2021
- Precision or Personalized Medicine | Precision Medicine ... - October 26th, 2021